https://www.selleckchem.com/products/cx-5461.html
Our study provides the rationale and critical data for a prospective clinical trial of losartan in patients with VS.Lung and bladder cancers are mostly incurable because of the early development of drug resistance and metastatic dissemination. Hence, improved therapies that tackle these two processes are urgently needed to improve clinical outcome. We have identified RSK4 as a promoter of drug resistance and metastasis in lung and bladder cancer cells. Silencing this kinase, through either RNA interference or CRISPR, sensitized tumor ce
Like
Comment
Share
